{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+I+Pancreatic+Cancer+American+Joint+Committee+on+Cancer+v8", "query": { "condition": "Stage I Pancreatic Cancer American Joint Committee on Cancer v8" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 26, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+I+Pancreatic+Cancer+American+Joint+Committee+on+Cancer+v8&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-25T23:00:11.761Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04539808", "title": "NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Adenocarcinoma", "Stage 0 Pancreatic Cancer American Joint Committee on Cancer v8", "Stage I Pancreatic Cancer American Joint Committee on Cancer v8", "Stage III Pancreatic Cancer American Joint Committee on Cancer v8", "Stage IV Pancreatic Cancer American Joint Committee on Cancer v8" ], "interventions": [ { "name": "Capecitabine", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Irinotecan Hydrochloride", "type": "DRUG" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Losartan Potassium", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Resection", "type": "PROCEDURE" }, { "name": "Diagnostic Imaging", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Nab paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2021-05-27", "completion_date": "2027-01-05", "has_results": true, "last_update_posted_date": "2026-01-14", "last_synced_at": "2026-06-25T23:00:11.761Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT04539808" }, { "nct_id": "NCT05687123", "title": "Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Pancreatic Neuroendocrine Tumor", "Pancreatic Neoplasm", "Stage III Pancreatic Neuroendocrine Tumor AJCC v8", "Stage IV Pancreatic Neuroendocrine Tumor AJCC v8", "Unresectable Pancreatic Neuroendocrine Tumor" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Lutetium Lu 177 Dotatate", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Sunitinib Malate", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2024-08-14", "completion_date": "2026-12-14", "has_results": false, "last_update_posted_date": "2026-05-13", "last_synced_at": "2026-06-25T23:00:11.761Z", "location_count": 9, "location_summary": "Duarte, California • Irvine, California • Orange, California + 4 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Shiloh", "state": "Illinois" }, { "city": "City of Saint Peters", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT05687123" }, { "nct_id": "NCT03784677", "title": "A Phase I Study of SOR-C13 in Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Refractory Malignant Solid Neoplasm", "Refractory Ovarian Carcinoma", "Refractory Pancreatic Carcinoma", "Stage II Pancreatic Cancer AJCC v8", "Stage IIA Pancreatic Cancer AJCC v8", "Stage IIB Pancreatic Cancer AJCC v8", "Stage III Ovarian Cancer AJCC v8", "Stage III Pancreatic Cancer AJCC v8", "Stage III Prostate Cancer AJCC v8", "Stage IIIA Ovarian Cancer AJCC v8", "Stage IIIA Prostate Cancer AJCC v8", "Stage IIIB Ovarian Cancer AJCC v8", "Stage IIIB Prostate Cancer AJCC v8", "Stage IIIC Ovarian Cancer AJCC v8", "Stage IIIC Prostate Cancer AJCC v8", "Stage IV Ovarian Cancer AJCC v8", "Stage IV Pancreatic Cancer AJCC v8", "Stage IV Prostate Cancer AJCC v8", "Stage IVA Ovarian Cancer AJCC v8", "Stage IVA Prostate Cancer AJCC v8", "Stage IVB Ovarian Cancer AJCC v8", "Stage IVB Prostate Cancer AJCC v8" ], "interventions": [ { "name": "TRPV6 Calcium Channel Inhibitor SOR-C13", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2019-07-29", "completion_date": "2023-06-20", "has_results": false, "last_update_posted_date": "2023-11-18", "last_synced_at": "2026-06-25T23:00:11.761Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03784677" }, { "nct_id": "NCT04809766", "title": "Mesothelin-Specific T-Cells (FH-TCR-Tᴍsʟɴ) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Pancreatic Ductal Adenocarcinoma", "Stage IV Pancreatic Cancer AJCC v8" ], "interventions": [ { "name": "Autologous Mesothelin-specific TCR-T Cells", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2021-12-14", "completion_date": "2025-01-15", "has_results": false, "last_update_posted_date": "2025-04-20", "last_synced_at": "2026-06-25T23:00:11.761Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT04809766" }, { "nct_id": "NCT05034627", "title": "Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Locally Advanced Pancreatic Adenocarcinoma", "Metastatic Pancreatic Adenocarcinoma", "Stage II Pancreatic Cancer AJCC v8", "Stage IIA Pancreatic Cancer AJCC v8", "Stage IIB Pancreatic Cancer AJCC v8", "Stage III Pancreatic Cancer AJCC v8", "Stage IV Pancreatic Cancer AJCC v8" ], "interventions": [ { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Calaspargase Pegol-mknl", "type": "DRUG" }, { "name": "Cobimetinib", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2022-08-09", "completion_date": "2026-10-01", "has_results": false, "last_update_posted_date": "2025-11-28", "last_synced_at": "2026-06-25T23:00:11.761Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT05034627" }, { "nct_id": "NCT06206876", "title": "FL118 for Treating Patients With Advanced Pancreatic Ductal Adenocarcinoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Pancreatic Ductal Adenocarcinoma", "Locally Advanced Pancreatic Ductal Adenocarcinoma", "Metastatic Pancreatic Ductal Adenocarcinoma", "Refractory Pancreatic Ductal Adenocarcinoma", "Stage II Pancreatic Cancer AJCC v8", "Stage III Pancreatic Cancer AJCC v8", "Stage IV Pancreatic Cancer AJCC v8", "Unresectable Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "DDX5 Degrader FL118", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2025-10-01", "completion_date": "2027-10-01", "has_results": false, "last_update_posted_date": "2025-01-17", "last_synced_at": "2026-06-25T23:00:11.761Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06206876" }, { "nct_id": "NCT04111172", "title": "A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Ductal Adenocarcinoma", "Colorectal Adenocarcinoma", "Gastric Adenocarcinoma", "Clinical Stage II Gastric Cancer AJCC v8", "Clinical Stage IIA Gastric Cancer AJCC v8", "Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8", "Clinical Stage IIB Gastric Cancer AJCC v8", "Clinical Stage III Esophageal Adenocarcinoma AJCC v8", "Clinical Stage III Gastric Cancer AJCC v8", "Malignant Solid Neoplasm", "Pathologic Stage II Gastric Cancer AJCC v8", "Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IIB Gastric Cancer AJCC v8", "Pathologic Stage III Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage III Gastric Cancer AJCC v8", "Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IIIA Gastric Cancer AJCC v8", "Pathologic Stage IIIB Gastric Cancer AJCC v8", "Pathologic Stage IIIC Gastric Cancer AJCC v8", "Stage I Pancreatic Cancer AJCC v8", "Stage IA Pancreatic Cancer AJCC v8", "Stage IB Pancreatic Cancer AJCC v8", "Stage II Pancreatic Cancer AJCC v8", "Stage IIA Pancreatic Cancer AJCC v8", "Stage IIB Pancreatic Cancer AJCC v8", "Stage III Colorectal Cancer AJCC v8", "Stage III Pancreatic Cancer AJCC v8", "Stage IIIA Colorectal Cancer AJCC v8", "Stage IIIB Colorectal Cancer AJCC v8", "Stage IIIC Colorectal Cancer AJCC v8", "Stage IV Colorectal Cancer AJCC v8", "Stage IVA Colorectal Cancer AJCC v8", "Stage IVB Colorectal Cancer AJCC v8", "Malignant Digestive System Neoplasm", "Small Intestinal Adenocarcinoma", "Stage III Small Intestinal Adenocarcinoma AJCC v8", "Stage IIIA Small Intestinal Adenocarcinoma AJCC v8" ], "interventions": [ { "name": "Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Thomas Jefferson University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2020-11-10", "completion_date": "2027-03-01", "has_results": false, "last_update_posted_date": "2025-08-22", "last_synced_at": "2026-06-25T23:00:11.761Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04111172" }, { "nct_id": "NCT05685602", "title": "CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Pancreatic Ductal Adenocarcinoma", "Stage III Pancreatic Cancer AJCC v8", "Stage IV Pancreatic Cancer AJCC v8", "Unresectable Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Emavusertib", "type": "BIOLOGICAL" }, { "name": "Gemcitabine Hydrochloride", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2023-06-12", "completion_date": "2027-04-30", "has_results": false, "last_update_posted_date": "2026-05-18", "last_synced_at": "2026-06-25T23:00:11.761Z", "location_count": 26, "location_summary": "Duarte, California • Irvine, California • Orange, California + 18 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05685602" }, { "nct_id": "NCT07651358", "title": "A Tailored, Web-based Program (COMPASS) to Improve Exercise and Dietary Changes in Stage I-III Pancreatic Cancer Patients Receiving Neoadjuvant Chemotherapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Stage I Pancreatic Cancer AJCC v8", "Stage II Pancreatic Cancer AJCC v8", "Stage III Pancreatic Cancer AJCC v8" ], "interventions": [ { "name": "Physical Activity and Nutritional Recommendations and Support", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2026-04-15", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-06-16", "last_synced_at": "2026-06-25T23:00:11.761Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT07651358" }, { "nct_id": "NCT03816358", "title": "Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Adenocarcinoma", "Stage II Pancreatic Cancer AJCC v8", "Stage III Pancreatic Cancer AJCC v8", "Stage IV Pancreatic Cancer AJCC v8" ], "interventions": [ { "name": "Anetumab Ravtansine", "type": "BIOLOGICAL" }, { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Gemcitabine Hydrochloride", "type": "DRUG" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 74, "start_date": "2019-12-09", "completion_date": "2027-01-31", "has_results": false, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-06-25T23:00:11.761Z", "location_count": 44, "location_summary": "Birmingham, Alabama • Duarte, California • Irvine, California + 35 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03816358" } ] }